K. R.M and R.B.S. contributed equally to this study Mannan-binding lectin (MBL) circulates in plasma in complex with MBL-associated serine proteases (MASP) -1, -2 and -3 and a smaller component, MApI9. When MBL binds to the surface of foreign material (microorganisms), MASP-l, -2, -3 are activated. MASP-2 then activates the complement system. MASP-l and -3 may activate other (unidentified) systems. MBL levels, MBL-bound MASP-l and MBL-bound MASP-2 activities have been evaluated in healthy individuals from UK and Armenian populations. MBL-bound MASP-2 activity declines in aging (P<O.04). MBL correlates with smoking (P<O.02). There were significant differences between the two populations in MBL-bound MASP-l activity and in MBL, but no difference in MBL-bound MASP-2 activity. When MASP activities were normalised to MBL (i.e, MASP-l activity/MBL, MASP-2 activity/MBL), normalised MASP-2 activity in UK individuals was more than 2 fold higher than in Armenians. The difference in normalised MASP-2 activity level between these two Caucasoid populations, suggests that concentration of the MBL-(MASP-2) complex, and therefore the function of activating complement, depends not only on the quantity of MBL in serum and its oligomeric state, but also on the quantity of MASP-2 in serum. It is likely that in individuals with high MBL concentration there is excess free MBL not occupied by MASPs, particularly not by MASP-2.
organism's first line of immune defence. The roles of MASP-l, MASP-3 and MAp 19 are not known yet. There is supposition that MASP-I augments (13) and MASP-3 down-regulates (4) the MASP-2 complement activation, but the data have not yet been confirmed. Also, MASP-l has a substrate reactivity profile similar to that of thrombin and cleaves fibrinogen and factor XIII (8) , but its physiological substrate has yet to be determined.
Deficiency of any or both MASP-I and MASP-3 has not yet been reported, but recently, one person with complete MASP-2 deficiency has been found in the Danish population (14) . However, inherited MBL deficiency is found as the most common human immune defect and occurs in most human population groups. MBL concentration is very variable between individuals, ranging from undetectable to about 20 mg/liter (average -1-2 mg/I). MBL deficiency predisposes to infections and some autoimmune diseases (15) (16) . Because of great variability in MBL concentration, activation of complement via the MBL pathway correlates broadly with circulating MBL protein quantity (17) (18) .
A body of evidence indicates that the complement-activating capacity of MBL and the MASPs is dependent on the oligomeric form of the MBL protein (4, (19) (20) . Dahl et al. (4) reported that MASP-l associates preferentially with smaller MBL oligomers and MASP-2 with larger MBL oligomers. Thus, high molecular weight MBL (tetramers to hexamers of structural subunits) was found to be capable of activating complement, whereas low molecular weight MBL (dimers, trimers) was less active. In addition to reported higher affinity for MASP-2, the larger MBL oligomers have increased avidity of binding to carbohydrate surfaces in comparison with lower oligomers, as they present multiple carbohydrate recognition domains (21) .
Our own recent work reinforces the concept that on average each MBL molecule does not simultaneously form complexes with several different MASPs. Instead it appears likely that each MBL circulates in complex with MASP-2, or with MASP-l, etc, but is unlikely to form MBL-(MASP-l )-(MASP-2) complexes. Excessfree MBL, not complexed with MASPs, is likely to occur in some individuals (22) .
Both MBL quantity and oligomeric state are mostly genetically determined by mutations in promoter and coding regions of the human MEL2 gene (22) (23) (24) . Nevertheless, non-genetic influences also significantly affect circulating MBL, as it is an acute phase protein (26) .
In this study, MBL levels and MASP-l/-2 activities have been evaluated in individuals randomly selected from Armenian and UK populations. This was done to gain information on inter-individual variation in MBL-MASP complex composition, to give insight into the stoichiometry of these complexes. The UK individuals had a mean MBL level similar to normal values reported for Caucasoids, but in contrast, the Armenians had a 2.5-fold higher mean (P<O.OOOl). It was found that the observed difference was not due to the frequency of low-level MBL producers in the populations, but due to the high-level MBL producers. Comparison of the data obtained also revealed significant differences in MBL-bound MASP-l activity, while MBL-bound MASP-2 activity has a similar level in both Caucasoid populations.
MATERIALS AND METHODS

Subjects
One hundred and fifty-two healthy volunteers randomly selected from two Caucasoid populations participated in the study: group 1 -physically and mentally healthy Armenian volunteers (AMV) (n=lOl, mean age M±SD, 34±9 years). All of them gave their informed consent to provide 5 ml of venous blood. The study was approved by local Ethics Committees. 17% of the Armenian subjects were smokers. Group 2 was adult blood donors from the UK population (UKV: n=51).
Blood sampling
Blood samples from the Armenian population (Yerevan, Armenia) were obtained from the antecubital vein into 3ml EDTA-vacutainers (n=82) or vacutainers without anti-coagulant (n= 19). Serum (after coagulation) and EDTA-plasma samples were prepared by separation ofcells after centrifugation and kept at -30°C. The samples were transferred from Armenia (Yerevan) to UK (Oxford) without any irradiation. EDTA-plasma samples were recalcified before use. Samples from the British population were obtained as whole blood aliquots (without anticoagulant) from the National Blood Transfusion Service, Bristol, UK. Serum samples were prepared from whole blood aliquots and kept at -20°C before use. Previous studies show that there is no difference between the two types of samples (re-calcified EDTA-plasma and serum) in the parameters investigated.
MBL purification
MBL was isolated from pooled human serum, for use as a quantitative assay standard, as described previously (27) (28) . This method involves precipitation of MBL from serum with 7% polyethylene glycol (PEG 3350), binding of MBL-MASP complexes to mannan-agarose, and elution with EDTA-containing buffer. MBL was separated from the MASPs by gel-filtration on Superose 6 (Pharmacia) at pH 5.0 in sodium acetate EDTA-containing buffer. Traces of IgM were removed by passage through an anti-IgM agarose column (Sigma-Aldrich, A9935). The MBL was estimated to be >98% pure by SDS-PAGE and its concentration was then established by amino acid analysis. Amino-acid analysis was done as described by Heinrikson and Meredith (29) .
Quantitation ofserum MBL by ELISA
MBL capable of binding to mannan was measured using an ELISA in which mannan-coated wells were used for capture of MBL (27) . Briefly, ELISA plates (Maxisorp, Nunc, Kamstrup, Denmark) were coated with 50~I of I mg/ml mannan (Sigma-Aldrich, M7504) in O.IM Na 2C03 , pH 9.6 (coating buffer). The wells were washed three times and blocked with PBS, 0.1% Tween-20 (w/v) for 2 h at RT. The wells were incubated for I h at RT with serum diluted 1/10-1/100 (v/v) in 10 mM HEPES, 1M NaCI, 5 mM CaCI 2 , pH 7.4. Negative control samples were diluted in 10 mM HEPES, 1M NaCI, 5 mM EDTA, pH 7.4 (to prevent MBL binding). The wells were washed and then incubated for I h at RT with 100 I ofa 1/250 (v/v) dilution of rabbit anti-MBL polyclonal antiserum (27) , depleted of anti-mannan antibodies by passage through a mannan agarose column (Sigma- Assay ofMASP-2 activity MBL-bound-MASP-2 activity was evaluated by C4 fixation assay as described by Presanis et al (30) . MBL-MASP complexes were bound to mannan-coated microtitre wells as for the MASP-I assay. After washing, purified human C4 (0.1 ug per well) in 20 mM HEPES, 140 mM NaCI, 5 mM CaCl z ' pH 7.4, was added to each well and incubated for I h at 37°C. Following three further washes with blocking buffer, 100 III alkalinephosphatase conjugated human anti-C4 (Immunsystem, Uppsala, Sweden) diluted 500-fold in blocking buffer was added and incubated for I h. Wells were washed three times with blocking buffer and developed using 100 III p-Nitrophenyl phosphate (Sigma-Aldrich) for I h at 37°C. The absorbance was read at 405 nm using a microtitre plate reader (Multiskan, ThermoLife Sciences).
MASP-2 mediated C4 cleavage activity was expressed in absorbance units per ml of serum (Vlml).
C4 Purification C4 was purified from fresh human serum by the method of Dodds (31) . C4 was dialyzed against 20 mM HEPES, 140 mM NaCl, pH7.4, frozen in 50 flg aliquots in liquid nitrogen and stored at -80 DC.
Statistics
Fisher's one-tailed exact test or median test was used for pairwise comparison of frequencies. The Shapiro-Wilk W test was done to determine the normality ofdistribution ofthe data obtained in each group. The two-tailed Mann-Whitney was used for comparison of the data obtained between groups. For correlation analysis of the data, Spearman's rank and Pearson correlations were applied when applicable. Statistics were performed using "Analyse-it" statistical software (Analyse-it Software Ltd., UK).
RESULTS
Serum MBL concentration
The median MBL serum level from the individuals tested was 1.9 ug/ml (range 20 ug/ml to undetectable level marked as 0). The sensitivity limit of the assay was 0.13 ug/rnl, The MBL concentrations of each of the groups are presented in Table I . The Armenian group had much higher MBL than the UK population. The mean MBL serum concentration of UK volunteers (UKV) was 1.21 ug/ml, which is similar to that found by Crosdale et al (32) and Kilpatrick (33) in UK Caucasoid individuals. From data obtained, the median serum MBL concentration of UKV was 2.7 fold lower than that of the AMV (Mann-Whitney, P<O.OOO 1), while the difference in mean values is 2.5 fold. However, the frequency of individuals with undetectable levels of MBL was not significantly different in both volunteer groups ( Fig. 1 Fisher's P=0.21). The observed difference in medians of the population groups was due to the different frequencies of individuals with high levels of MBL. From Fig. 2 it is obvious that in the AMV the proportion of individuals with a serum MBL concentration more than 2 ug/rnl was 60%, but in UKV it was 24% (Fisher's P<O. OOO 1) . The difference between these two Caucasoid populations was also due to the higher mean MBL levels in the highest concentration range. Armenians with more than 2 ug/ml serum MBL on average had 4.7 ug/rnl MBL, while the corresponding UKV subset had only 2.9 Ilg1 ml (Mann-Whitney, P<0.006). However, individuals representing the other concentration frames had similar average (and SD) MBL concentration in both population groups (Fig. 1) .
MASP-J activity
The median MBL-bound MASP-l activity in all of the investigated individuals was 0.92 RFU (range 0-14.88 RFU: lower detection limit of the assay is about 20 ng/ml). The MASP-l activity characteristics of each group are shown in Table I . There was a highly significant difference between the UK and Armenian groups (Mann-Whitney, P<0.003). The median of MASP-l activity in UKV was approximately 4.2 fold lower than that in AMY. Although the frequency of individuals with undetectable MASP-l activity did not differ significantly between both groups (Fisher's P=0.32), the median test for both groups (less and equal, and greater than overall median of 0.92 RFU) revealed a significant difference in frequencies of individuals (Fisher's P=0.0035). In comparison with Armenians (59%), approximately two-fold fewer UK volunteers (32%) had MASP-l activity greater than the overall median.
There was a strong correlation between the data obtained on serum MBL level and MASP-l activity for each of the investigated groups (AMV, Spearman's rank rs = 0.78, UKV, rs =0.93, in each case P<O.OOOI). This is expected as we are measuring MASP-l bound to the plate via MBL. Of the 30 individuals with undetectable MBL-bound MASP-l activity, most also had no detectable MBL. However, two UKV with undetectable MASP-l activity had low but detectable MBL (0.13-0.14 ug/ml). In the Armenian population, one had 0.75 ug/ml MBL, and one had high MBL (4.1 ug/rnl), but undetectable MASP-l. Each of these 4 individuals had MASP-2 activity. These 4 cases may indicate some form of MASP-l deficiency, and further studies are being done to investigate this.
MASP-2 activity
The median MBL-bound MASP-2 activity in all of the investigated individuals was 6.31 U/ml (range 0-10.83U/ml: lower detection limit ofthe assay is about 2 ng/ml). Only two individualshad undetectable MASP-2 
Fig. I. Frequency distributions of individuals by serum MBL level: Armenian volunteers (AMV) vs. UK volunteers (UKV). Center (labeled) and radius ofcircles indicate mean and SD ofthe serum MBL levels. respectively. in different
concentration ranges: 1) undetectable concentration (lower detection limit ofthe assay is 0.13 ug/ml); 2) from 0.13 to 1 ug/ml; 3)from 1 to 2 pglml; 4) more than 2 ug/ml (*P<0.006). activity (one from Armenian and one from UK groups) . Both had undetectable MBL. In contrast to MASP-I activity most of the individual s with undetectable MBL serum concentration had detectable MASP-2 activity. This apparent anomaly arises from the greater sensitivity of the MASP-2 assay. MASP-2 activity distribution characteristics of each group are seen in Table I . The median MASP-2 activity of UKV was not different from that of the AMV group (Mann-Whitney, P<0.99). In both investigated groups MASP-2 activity positively correlated with MBL serum level (AMV, rs = 0.61, UKV, rs = 0.8, in both cases p<O.OOO I). MASP-2 activity correlated positively with MASP-I activity only in UKV group (UKV, rs =0.6, P<O.OOO I; AMY, rs =0.21, P<O.066; Fig. 2 ). In both groups , however, the correlation of MASP-2 with MASP-I was non-linear. The MASP-2 activity level increased with MASP-I activity up to 3RFU MASP-I level. Above this MASP-I level, MASP-2 activity declined with increasing MASP-I . The best-fit equat ion for the correlation of the activity levels of both MASPs in UKV group was y=-OAIX2+2.57X+5.9, where "y" is MASP-2 activity and "x" is MASP-l activity (Fig. 2a ).
MBL-bound MASP-J and -2 activities normalized to MBL concentration
MASP-I and MASP-2 activity per J.1g of MBL was calculated (referred to as nMASP-I acti vity and nMASP-2 activity) from each individual. The data for individuals with undetectable MBL serum concentration were not included in the calculation. The ratio MBL-bound MASP acti vity/MBL concentration was expressed in arbitrary un its (nMASP-2 activity: AU ; nMASP-I activity: ARFU). However, as the frequency of individuals with undetectable levels of MBL was not significantly different in both groups (Fisher's P=0.21), the results obtained are descriptive and correct from a viewpoint of population considerations.
The med ian nMASP-2 activity of all investigated subjects was 3.35 AU . The data obtained for both groups are shown in Table I . There was a great difference between UKV and AMV in the nMASP-2 act ivity. The median of this parameter in UKV was 2.32 fold higher than that of the AMV (Mann-Whitney, P<O.OOOI).
The median test for the two volunteer groups (less and equal, and greater than overall median: 3.35 AU) revealed a significant difference in frequencies of individuals (Fisher 's P=O.OOO 1). In comparison with AMV (34%), UKV (84%) had a 2.5 times higher frequency of individuals with nMASP- 2 activity greater than the overall median. Unlike the nMASP-2 activity, nMASP-l activity did not exhibit significant difference between the UKV and AMV (Table I , Mann-Whitney, P<0.15).
Y=-OA1x
The correlation of the data on nMASP-l and nMASP-2 activities in individuals from the UK population showed a negative non-linear correlation (rs =-0.55, P<0.0004). The Armenian data (AMV) gave similar non-linear profiles (rs =-0.26, P<0.02). This means that high nMASP-l is generally associated with low nMASP-2, and vice-versa.
Strikingly, although the nMASP-2 activity was not correlated with (non-normalized) MASP-2 activity (Fig. 3c, 4c ), it has negative (inverse) correlation with MBL level (UKV, rs =-0.97, P<O.OOOI; AMV, rs =-0.93, P<O.OOOI; Fig. 3a, 4a ) and (non-normalized) MASP-l activity (UKV, rs =-0.81, P<O.OOOI; AMV, rs =-0.66, P<O.OOOI, Fig.  3b, 4b ). In Fig. 3 and 4 , in both groups the best-fit equation for the correlation was y=a/x, where "y" is nMASP-2 activity and "x" is either [MBL] or (nonnormalized) MASP-l activity.
The nMASP-l activity in UKV was positively correlated with [MBL] (rs =0.67, P<O.OOOl), with (non-normalized) MASP-l (rs =0.93, P<O.OOOI) and with MASP-2 activities (rs =0.64, P<O.OOOI). In the AMV group it had a positive correlation only with MASPI activity (non-normalized) (rs =0.75, P<O.OOOI). There was no correlation between nMASP-l activity and either [MBL] (rs =0.16, P<0.15) or (non-normalized) MASP-2 activity (rs =-0.16, P<0.17).
Correlation with demographic data
The results of correlation analysis of all parameters investigated and demographic data (age, gender, smoking, alcohol use) of the individuals from AMV group are presented in Table II . As shown here, there is negative correlation between age and MASP-2 activity (Pearson's uncorrected P<0.036), which indicates that MASP-2 activity declines with aging. The other interesting result is that MBL concentration is correlated with smoking (Pearson's uncorrected P<O. O 19) . In this case the explanation could be the fact that the MBL is an acute phase protein (34) , and as smoking is suggested to cause a mild acute-phase immune response, smokers could have higher MBL level than non-smokers. To test this hypothesis we performed a statistical comparison of MBL concentration in smokers vs non-smokers within the AMV group, which revealed that smokers (M±SD: 5.31±1.49 ug/rnl; median 3.27 ug/ml) have two-fold higher average MBL concentration than non-smokers (M±SD: 2.89±0.29 ug/ml; median 2.96 ug/rnl; P<O.OI). There were no correlations of MASP-l and MASP-2 activities and MBL level with regard to alcohol use and gender.
DISCUSSION
We found that there is a great difference in baseline MBL serum level between UK and Armenian groups (P<O.OOOI). The UKV had a mean MBL concentration that was consistent with published normal values for Caucasoids (23, (32) (33) (34) . In contrast, the Armenians had a mean value 2.5 times higher than those previously reported for Caucasoids (M±SD: 3.048±3.07 ug/ml). The observed difference was not due to the frequency of low-level MBL producers (MBL<0.19 ug/ml, Fisher's -P<0.2) in each population group, but because ofthe high-level MBL producers (MBL>2.2 ug/ml Fisher's P<O.OOOI). Appropriate upper and lower MBL levels for lowlhigh-Ievel MBL producers were chosen corresponding to the data provided for British Caucasoids by Crosdale et al (32) .
A large difference was also found between the population groups in MASP-l activity. As with MBL levels, the UK population group had a lower MASP-I activity than the AMV (P<0.003). The MASP-l assay measures MBL-bound MASP-l activity and so a strong correlation, in both populations, between MBL level and MASP-l activity (P<O.OOO 1) is to be expected. Correspondingly, nMASP-l activity (MASP-l activity calculated per ug of MBL) in the bound MBL-MASP complexes was not significantly different between population groups (Table I, P<0.15) . The biological significance of MASP-I has not yet been defined, as a physiological substrate has yet to be determined. However, participation of MASP-I in cross-linked fibrin clot formation may well reflect an aspect of innate immunity (8) . Immobilisation of bacteria by fibrin mesh formation has been shown to retard bacterial spread and migration to the bloodstream in peritoneal infection (35) (36) . Fibrinopeptide B, which is released from fibrinogen by MASP-l action (8) , is a potent chemotactic factor for neutrophils similar to C5a (37), as well as for fibroblasts and monocytes (19, 38) . An opsonic role of deposited fibrin was reported in 1978 (37) , but this issue has not been thoroughly investigated.
The data comparison on MBL-bound MASP-2 activity did not reveal any difference between the UK and Armenian groups (P<0.99). The MASP-2 activity assay used measures activity of MASP-2 bound to MBL. So it is expected that MASP-2 activity and MBL concentration will correlate. There was positive correlation in both population groups between MASP-2 activity and MBL level (in both populations P<O.OOOI). nMASP-2 activity (MASP-2 activity normalized per ug MBL) however, showed a difference of>2-fold between populations with the UKV group having a higher median (Table I) . This suggests that although the AMV group has higher MBL, their capacity to activate complement via MBL is not elevated as their MBL-bound MASP-2 activity is not greater than for UKY.
Among the MASPs, only MASP-2 has a clearly defined role in complement fixation. Upon autoactivation, it cleaves complement components C4 and C2, and triggers complement activation (10) . It was previously suggested that the MASPs do not limit complement MBL-pathway activation, as a large proportion of the MASPs was thought to exist in a form not complexed to MBL in the circulation (4, 39) . However, recent observations indicate that there is no free MASP-2 in plasma and all MASP-2 is bound in complex with MBL or with L-and H-ficolins (40) . Total MASP-2 levels in plasma of healthy individuals (Danish population) do not follow a normal distribution and range from 170 to 1196 ng/ml with mean value 534±213 ng/ml (M±SD; median 497 ng/ml). Moreover, MASP-2 level is not correlated with MBL plasma concentration (40) .
Assuming a mean MBL level of 1.2 ug/ml (UK population) MBL alone could bind 480-960 ng of MASP-2, depending on whether the calculation is done for an MBL hexamer (18 polypeptides) binding one MASP-2 dimer, or for an MBL trimer (9 polypeptides) binding one MASP-2 dimer. L-ficolin and H-ficolin are present in plasma and also bind MASP-2 (41) . The ficolins are at higher average concentration than MBL (4-14 ug/rnl L-ficolin, 7-23 ug/ml for H-ficolin). Thus the available MASP-2 will be distributed between MBL and the ficolins. Based on the average concentrations listed above, and comparable binding affinity of MASP-2 for MBL and the ficolins (41), only 3 to 11 out of 100 MBL molecules will have MASP-2 associated with them. A higher number of MBL molecules is likely to have MASP-l attached (2-3 fold higher) (42) . Both MASP-3 and MAp 19 are of low abundance in plasma, so a proportion of the MBL is likely to be "empty", without bound MASPs.
Our results show that there is an inverse correlation between nMASP-2 activity (normalised) and MBL for both UKV and AMY. This means that individuals with high MBL have low occupancy of the MBL with MASP-2, while individuals with low MBL have high occupancy of the MBL with MASP-2 ( Fig. 3 and 4 ). nMASP-2 activity also has inverse correlation with MASP-l activity ( Fig. 3 and 4) , and with nMASP-l activity (22) . Thus on average, a high level of MASP-l bound to MBL correlates with a low level of MASP-2 bound to MBL, but with wide inter-individual variation. In the present study Fig. 2 shows that above a threshold of MASP-l quantity, additional MASP-l competes out the binding of MASP-2. MASP-2 activity level increases with MASP-l activity up to about 3RFU MASP-l activity level. Above this MASP-l level, MASP-2 activity declines with increasing MASP-l. The best-fit equation for this correlation of the MASPs activities was seen for the UKV group ( Fig. 2a ; y=-0.41X2+2.57X+5.9). This group had relatively lower MBL level on average, therefore, would be expected to show more clearly the competition between MASPs for available MBL.
Concerning the relationship of MASP-2 activity with nMASP-2 activity, there was no correlation of any kind between them. The nMASP-2 activity is an indicator of the effective fraction of MBL-MASP complexes capable of activating the complement system, as it shows the portion of MBL-(MASP-2)2 complexes in the whole MBL-MASP complex population (22) . From this we could hypothesise that MBL-(MASP-2)2 complex formation does not depend only on MBL quantity and oligomeric state programmed by genotype, as has been suggested, but also depends on quantities of MASPs. From these correlation results, we may suggest that, above a relatively low MBL threshold level, MBL-(MASP-2)2 complex formation is mostly limited by MASP-2 quantity in blood and not by MBL.
The results that in comparison with UKV, AMV have higher MBL concentration but equal MBLbound MASP-2 activity, predict that in circulation AMV have many more MBL molecules free from MASP-2 than UKY. So these Caucasoid populations do differ from each other in degrees of MBL occupancy with MASPs.
